Latest news
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - MorningstarMorningstar · Mon, 10 Aug 2026 11:00:00 GMTFavorable Phase 1 Data for Orexin-2 Agonist BP-205, Broader Pipeline Progress Headline Harmony's Q2 Update - NeurologyLiveNeurologyLive · Thu, 06 Aug 2026 23:10:51 GMT